 DUBLIN GAITHERSBURG, Md.--BUSINESS WIRE--Horizon Therapeutics plc Nasdaq: HZNP and Viela Bio, Inc. Nasdaq: VIE today announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio, Inc. common stock for 53.00 per share in cash, which represents a fully diluted equity value of approximately 3.05 billion, or approximately 2.67 billion net of Vielas cash and cash equivalents. As previously announce 